The US Food and Drug Administration (FDA) approved late Tuesday a new nonstimulant therapy for attention deficit hyperactivity disorder (ADHD), with the promise of fewer side effects and no risk of addiction.
The FDA approved Eli Lilly and Company’s Strattera (atomoxetine HCl), the first new type of drug to be approved for the common childhood disorder in nearly three decades.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!